Tofersen

Therapeutic indications

Tofersen is indicated for:

Amyotrophic lateral sclerosis with a mutation in the superoxide dismutase 1 gene

Population group: only adults (18 years old or older)

Tofersen is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Tofersen is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: QALSODY Solution for injection
Structured Product Labeling (SPL/PLR) 2023: QALSODY Solution for injection
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈